PCBP4 Inhibitors
Chemical inhibitors of PCBP4 can exert their inhibitory effects through a variety of mechanisms involving the disruption of cell cycle regulation and RNA metabolic processes. Alsterpaullone and Roscovitine, both cyclin-dependent kinase (CDK) inhibitors, can lead to altered phosphorylation states of proteins that interact with PCBP4, thereby inhibiting PCBP4's function in RNA binding and regulation. Similarly, Tozasertib, an inhibitor of Aurora kinases, and SNS-032, which targets CDKs 7, 9, and 2, can disrupt cell cycle-related processes and transcription regulation that are essential for PCBP4's activity. Flavopiridol, another CDK inhibitor, can impede the phosphorylation of transcription factors and other proteins integral to PCBP4's functionality in RNA processing.
Gö6976's inhibition of protein kinase C (PKC) isoforms and Wortmannin's targeting of phosphatidylinositol 3-kinase (PI3K) can attenuate the signaling pathways that influence the activity of proteins interacting with PCBP4. This attenuation can lead to a decrease in PCBP4's RNA-binding and regulatory functions. U0126, by inhibiting MEK1/2, disrupts the ERK pathway, which can affect the function of RNA-binding proteins and, consequently, PCBP4's role. Rapamycin, an mTOR inhibitor, suppresses the upstream signaling that regulates RNA-binding proteins like PCBP4, thus inhibiting its function within the protein synthesis and cell growth pathways. LY294002, another PI3K inhibitor, can disrupt downstream signaling pathways that affect cellular processes involving PCBP4, including its role in RNA stabilization and translation. Additionally, 5-Iodotubercidin raises adenosine levels, affecting adenosine-dependent protein kinases and potentially altering the phosphorylation state and activity of proteins associated with PCBP4. Indirubin-3'-monoxime's inhibition of GSK-3β can also alter the phosphorylation state and activity of proteins associated with PCBP4, leading to a decrease in PCBP4's functional activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is a known inhibitor of cyclin-dependent kinases (CDKs). Given that PCBP4 regulates RNA stability and is involved in cell cycle regulation, CDK inhibition by Alsterpaullone can lead to altered phosphorylation states of proteins that interact with PCBP4, inhibiting PCBP4's function in RNA binding and regulation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine is another CDK inhibitor that can suppress the phosphorylation of proteins that are crucial for cell cycle progression. Inhibition of these kinases can prevent the proper function of PCBP4 in cell cycle regulation by disrupting the phosphorylation-dependent interactions of PCBP4 with its target RNAs. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
This compound is a selective inhibitor of CDKs and GSK-3β. GSK-3β is involved in many signaling pathways that could intersect with PCBP4's roles in RNA metabolism. By inhibiting GSK-3β, the phosphorylation state and activity of proteins associated with PCBP4 could be altered, leading to a decrease in PCBP4 functional activity. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $150.00 $455.00 | 20 | |
5-Iodotubercidin is an adenosine kinase inhibitor that raises the levels of adenosine, which can affect various adenosine-dependent protein kinases. These kinases could phosphorylate proteins that interact with or regulate PCBP4, thus inhibiting PCBP4's RNA-binding function by changing its interaction landscape. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $61.00 $85.00 | 4 | |
Tozasertib is a potent inhibitor of Aurora kinases which are involved in cell cycle control. Since PCBP4 is implicated in the regulation of mRNA stability during cell cycle progression, inhibition of Aurora kinases can disrupt this process and thereby inhibit PCBP4's function. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a specific inhibitor of CDKs 7, 9, and 2. By inhibiting these CDKs, the compound can hinder the phosphorylation of substrates involved in RNA processing and transcription regulation, potentially inhibiting the functional activity of RNA-binding proteins like PCBP4. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol is a CDK inhibitor that can inhibit the phosphorylation of transcription factors and other proteins that may be necessary for the proper functioning of PCBP4 in RNA processing and metabolic regulation. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
Gö6976 is a potent inhibitor of protein kinase C (PKC) isoforms. PKC-mediated phosphorylation can regulate the activity of a wide range of proteins, including those that may interact with PCBP4. Inhibiting PKC can thus reduce the functional activity of PCBP4 indirectly. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent phosphatidylinositol 3-kinase (PI3K) inhibitor. PI3K signaling can regulate various aspects of RNA metabolism and protein synthesis, potentially affecting proteins that interact with PCBP4. Inhibition of PI3K can therefore inhibit PCBP4's role in RNA regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. The ERK pathway can influence RNA binding protein function, and inhibiting MEK can disrupt the phosphorylation and activity of downstream targets that may regulate PCBP4 function. | ||||||